Peripheral-blood stem cells versus bone marrow from unrelated donors

New England Journal of Medicine

Volumn 367, Issue 16, 2012, Pages 1487-1496

  Anasetti, Claudio ^a   Logan, Brent R ^c   Lee, Stephanie J ^d   Waller, Edmund K ^e   Weisdorf, Daniel J ^f   Wingard, John R ^b   Cutler, Corey S ⁱ   Westervelt, Peter ^j   Woolfrey, Ann ^d   Couban, Stephen ^k   Ehninger, Gerhard ^m   Johnston, Laura ⁿ   Maziarz, Richard T ^o   Pulsipher, Michael A ^p   Porter, David L ^q   Mineishi, Shin ^r   McCarty, John M ^s   Khan, Shakila P ^g   Anderlini, Paolo ^t   Bensinger, William I ^d   Leitman, Susan F ^u   Rowley, Scott D ^w   Bredeson, Christopher ^l   Carter, Shelly L ^v   Horowitz, Mary M ^c   Confer, Dennis L ^h   more..

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e EMORY UNIVERSITY   (United States)

^f UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^g MAYO CLINIC   (United States)

^h NATIONAL MARROW DONOR PROGRAM   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j USA   (United States)

^k DALHOUSIE UNIVERSITY   (Canada)

^l UNIVERSITY OF OTTAWA   (Canada)

^m UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

ⁿ STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^o OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^p UNIVERSITY OF UTAH   (United States)

^q UNIVERSITY OF PENNSYLVANIA   (United States)

^r UNIVERSITY OF MICHIGAN   (United States)

^s VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^t UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^u NATIONAL INSTITUTES OF HEALTH   (United States)

^v EMMES CORPORATION   (United States)

^w HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; MELPHALAN; METHOTREXATE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELOPROLIFERATIVE DISORDER; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOM SAMPLE; RELAPSE; RISK REDUCTION; SURVIVAL RATE; UNRELATED DONORS;

EID: 84867592111     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1203517     Document Type: Article

References (30)

1. Russell NH, Hunter A, Rogers S, Hanley J, Anderson D. Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet 1993;341:1482.
2. Dreger P, Suttorp M, Haferlach T, Löffler H, Schmitz N, Schroyens W. Allogeneic granulocyte colony-stimulating factormobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. Blood 1993;81:1404-7.
3. Körbling M, Przepiorka D, Huh YO, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995;85:1659-65.
4. Schmitz N, Dreger P, Suttorp M, et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995;85:1666-72.
5. Bensinger WI, Weaver CH, Appelbaum FR, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995;85:1655-8.
6. Blaise D, Kuentz M, Fortanier C, et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with earlystage leukemia: a report from the SociétéFrançaise de Greff e de Moelle. J Clin Oncol 2000;18:537-46.
7. Powles R, Mehta J, Kulkarni S, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000;355:1231-7.
8. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001;344:175-81.
9. Morton J, Hutchins C, Durrant S. Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 2001;98:3186-91.
10. Couban S, Simpson DR, Barnett MJ, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002;100:1525-31.
11. Schmitz N, Beksac M, Hasenclever D, et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 2002;100:761-7.
12. National Marrow Donor Program homepage (http://www.marrow.org).
13. Eapen M, Logan BR, Confer DL, et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant 2007;13:1461-8.
14. Lin DY. Non-parametric inference for cumulative incidence functions in competing risks. Stat Med 1997;16:901-10.
15. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-17.
16. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-56.
17. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007;110:4576-83.
18. Sierra J, Storer B, Hansen JA, et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 1997;89:4226-35.
19. Petersdorf EW, Hansen JA, Martin PJ, et al. Major-histocompatibility- complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med 2001;345:1794-800.
20. Spellman S, Bray R, Rosen-Bronson S, et al. The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood 2010;115:2704-8.
21. Guardiola P, Runde V, Bacigalupo A, et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 2002;99:4370-8.
22. Switzer GE, Harrington D, Haagenson MD, et al. Health-related quality-of-life among adult matched unrelated stem cell donors: a Blood and Marrow Transplant Clinical Trials Network (BMT CTN) randomized trial of marrow versus PBSC donation. Presented at the 52nd ASH Annual Meeting and Exposition, Orlando, FL, December 4-7, 2010. abstract.
23. Pasquini MC, Wang Z, Horowitz MM, Gale RP. 2010 Report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clin Transpl 2010;2010:87-105.
24. Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005;23:5074-87.
25. Pidala J, Anasetti C, Kharfan-Dabaja MA, Cutler C, Sheldon A, Djulbegovic B. Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009;15:1415-21.
26. Oehler VG, Radich JP, Storer B, et al. Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. Biol Blood Marrow Transplant 2005;11:85-92.
27. Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002;100:415-9.
28. Friedrichs B, Tichelli A, Bacigalupo A, et al. Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol 2010;11:331-8.
29. Bacigalupo A, Lamparelli T, Barisione G, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006;12:560-5.
30. Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009;10:855-64.